Texas Gov. Greg Abbott on June 11 signed a bill creating a consortium of universities, hospitals and pharmaceutical firms to conduct clinical trials on ibogaine, in hopes of receiving US Food & Drug Administration approval. The press release on the signing hails ibogaine as an "emerging treatment for neurological and mental health conditions." Lawmakers approved $50 million to support the effort, making Texas the global leader in psychedelic research investment. (Texas Tribune)


Next week, the Multidisciplinary Association for Psychedelic Studies (MAPS) will bring a host of psychedelic scientists and visionary artists together in San Jose, California for the largest conference of its kind in the U.S. in 17 years.





Recent comments
2 weeks 1 day ago
5 weeks 6 days ago
9 weeks 6 days ago
10 weeks 5 days ago
20 weeks 5 days ago
24 weeks 5 days ago
25 weeks 5 days ago
25 weeks 6 days ago
46 weeks 6 days ago
51 weeks 13 hours ago